Video Experimental Relacionado

Updated: Aug 17, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Síntomas neuropsiquiátricos durante el tratamiento con interleucina-2 e interferón alfa

M H Fenner, E L Hänninen, H H Kirchner

    Lancet (London, England)
    |February 6, 1993
    PubMed
    Resumen

    No abstract available in PubMed .

    Más Videos Relacionados

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
    09:38

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

    Published on: September 12, 2016

    Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
    09:57

    Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

    Published on: June 28, 2021

    Videos de Experimentos Relacionados

    Last Updated: Aug 17, 2026

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
    10:00

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

    Published on: March 24, 2015

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
    09:38

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

    Published on: September 12, 2016

    Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
    09:57

    Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

    Published on: June 28, 2021

    Videos de Conceptos Relacionados

    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    T Cell Types and Functions01:24

    T Cell Types and Functions

    When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
    Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ACERCA DE JoVE
    Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
    AUTORES
    Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
    BIBLIOTECARIOS
    TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
    INVESTIGACIÓN
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
    EDUCACIÓN
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
    Términos y Condiciones de Uso
    Política de Privacidad
    Políticas
    Jove
    Visualize
    Contáctanos